CD20-negative large-cell lymphoma with plasmablastic features: A clinically heterogenous spectrum in both HIV-positive and -negative patients Journal Article
| Authors: | Teruya-Feldstein, J.; Chiao, E.; Filippa, D. A.; Lin, O.; Comenzo, R.; Coleman, M.; Portlock, C.; Noy, A. |
| Article Title: | CD20-negative large-cell lymphoma with plasmablastic features: A clinically heterogenous spectrum in both HIV-positive and -negative patients |
| Abstract: | Background: Plasmablastic lymphoma (PBL) has been described as a rapidly progressive and almost invariably fatal CD20- VS38c+ diffuse large-cell lymphoma with plasmablastic features, almost exclusively involving the jaw and oral mucosa in HIV-positive patients. Methods: From 2001 to 2003 we evaluated 12 men with PBL, and report the pathology, clinical findings, treatment and outcome. Six of 12 were HIV-positive while among the others, one was post-renal transplant, one had ulcerative colitis and four had no known immunodeficiency. Results: Tumor growth pattern, in general, showed cohesiveness and a starry-sky pattern; the morphology varied from typical plasmablastic to centroblastic cells. Partial immunophenotypes were (+/total): CD138, 11 of 12 (91.7%); MIB1 10 of 11 (4+, range 75-95%); p63/VS38c, nine of 10 (90%); EBV, eight of 11 (73%); LCA(CD45), two of 12 (16.7%); HHV8/LANA, zero of 10; ALK, zero of seven; and CD20, zero of 12. Three had stage IE and nine stage IV disease. Nine of 12 had an intermediate/high International Prognostic Index or high-risk disease. Computed tomography and positron emission tomography scan in four of 12 revealed extensive bone metastases. Seven of 12 patients are alive with no evidence of disease at a median follow-up of 15 months (range 7-27+). Of the HIV-positive patients, five of six are alive with a median follow-up of 17 months. Conclusions: It appears that PBL are heterogenous in terms of clinical presentation and morphology. The outcome presented here is superior to that originally reported. © 2004 European Society for Medical Oncology. |
| Keywords: | adult; clinical article; controlled study; human tissue; treatment outcome; aged; middle aged; survival analysis; survival rate; clinical feature; histopathology; postoperative period; bone metastasis; human immunodeficiency virus infection; follow up; follow-up studies; ki 67 antigen; computer assisted tomography; cohort studies; high risk patient; cd20 antigen; antigens, cd20; computer assisted emission tomography; tumor cell; immunophenotyping; protein p63; ulcerative colitis; large cell lymphoma; tumor growth; immune deficiency; epstein barr virus; cd45 antigen; hiv infections; human herpesvirus 8; clinical examination; kidney transplantation; epstein-barr virus infections; syndecan 1; latency associated nuclear antigen; plasmablastic lymphoma; lymphoma, large-cell; humans; human; male; priority journal; article; ebv-positive; hiv-positive/negative patients |
| Journal Title: | Annals of Oncology |
| Volume: | 15 |
| Issue: | 11 |
| ISSN: | 0923-7534 |
| Publisher: | Oxford University Press |
| Date Published: | 2004-11-01 |
| Start Page: | 1673 |
| End Page: | 1679 |
| Language: | English |
| DOI: | 10.1093/annonc/mdh399 |
| PROVIDER: | scopus |
| PUBMED: | 15520070 |
| DOI/URL: | |
| Notes: | Ann. Oncol. -- Cited By (since 1996):101 -- Export Date: 16 June 2014 -- CODEN: ANONE -- Source: Scopus |
Altmetric
Citation Impact
BMJ Impact Analytics
Related MSK Work